Renaissance Technologies
MRKR icon

Renaissance Technologies’s Marker Therapeutics MRKR Stock Holding History

Renaissance Technologies’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$286K Buy
267,350
+17,927
+7% +$22.7K ﹤0.01% 2803
2026
Q2 		$367K Buy
249,423
+74,129
+42% +$108K ﹤0.01% 2714
2026
Q1 		$228K Buy
175,294
+51,644
+42% +$81.9K ﹤0.01% 2885
2025
Q4 		$184K Buy
123,650
+17,400
+16% +$19.7K ﹤0.01% 2903
2025
Q3 		$94.8K Buy
106,250
+36,808
+53% +$45.4K ﹤0.01% 3260
2025
Q2 		$106K Sell
69,442
-14,073
-17% -$18.1K ﹤0.01% 3290
2025
Q1 		$103K Buy
83,515
+43,465
+109% +$79.6K ﹤0.01% 3198
2024
Q4 		$125K Buy
40,050
+300
+0.8% +$1.06K ﹤0.01% 3253
2024
Q3 		$112K Buy
39,750
+900
+2% +$3.56K ﹤0.01% 3242
2024
Q2 		$211K Buy
38,850
+1,600
+4% +$6.8K ﹤0.01% 3029
2024
Q1 		$160K Sell
37,250
-300
-0.8% -$1.31K ﹤0.01% 3276
2023
Q4 		$207K Sell
37,550
-2,700
-7% -$9.15K ﹤0.01% 3122
2023
Q3 		$183K Buy
40,250
+8,300
+26% +$46.4K ﹤0.01% 3116
2023
Q2 		$99K Buy
31,950
+12,600
+65% +$21.9K ﹤0.01% 3476
2023
Q1 		$14K Buy
19,350
+3,030
+19% +$7.2K ﹤0.01% 3865
2022
Q4 		$43K Buy
16,320
+1,170
+8% +$4.04K ﹤0.01% 3825
2022
Q3 		$56K Sell
15,150
-11,620
-43% -$42.7K ﹤0.01% 3727
2022
Q2 		$88K Sell
26,770
-31,657
-54% -$105K ﹤0.01% 3879
2022
Q1 		$257K Sell
58,427
-48,473
-45% -$277K ﹤0.01% 3538
2021
Q4 		$1.02M Buy
106,900
+8,390
+9% +$111K ﹤0.01% 2624
2021
Q3 		$1.66M Buy
98,510
+58,520
+146% +$1.2M ﹤0.01% 2230
2021
Q2 		$1.12M Buy
+39,990
New +$1.05M ﹤0.01% 2617
2021
Q1 		– Sell
-31,836
Closed -$462K – 3566
2020
Q4 		$462K Buy
31,836
+9,136
+40% +$142K ﹤0.01% 2855
2020
Q3 		$341K Sell
22,700
-9,262
-29% -$169K ﹤0.01% 2952
2020
Q2 		$662K Buy
31,962
+8,492
+36% +$186K ﹤0.01% 2762
2020
Q1 		$446K Buy
23,470
+11,560
+97% +$294K ﹤0.01% 2814
2019
Q4 		$343K Buy
+11,910
New +$433K ﹤0.01% 3037

Other funds holding MRKR

Aisling Capital Management
Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Ashton Thomas Private Wealth
Ashton Thomas Private Wealth Scottsdale, Arizona $4.98B AUM 21.09% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Renaissance Technologies's MRKR Position: Q3 2026 in Review

Renaissance Technologies increased its Marker Therapeutics (MRKR) stake by 7.2% in Q3 2026, buying an estimated $22.7K and bringing the position to 267,350 shares worth $286K. The position accounts for ﹤0.01% of the portfolio, ranked #2803.

Renaissance Technologies first reported a position in MRKR in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.66M in Q3 2021. 22 funds tracked by Wall St. Rank hold MRKR as of Q3 2026.

  • Renaissance Technologies held 267,350 shares of Marker Therapeutics worth $286K as of Q3 2026.
  • Renaissance Technologies bought 17,927 Marker Therapeutics shares in Q3 2026, an estimated $22.7K.
  • Marker Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q3 2026, its #2803 holding.
  • Renaissance Technologies first reported a position in Marker Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • Renaissance Technologies's Marker Therapeutics position peaked at $1.66M in Q3 2021.
  • 22 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2026.

Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.